Available on Alexa:

2018 CMHC West Expert Interview:
Non-Statin Drugs and New Approaches

Credit Type(s) Available:

ACCME, CDR, ACPE, ANCC

Maximum Credits:

0.5

Provided By:

This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.

Commercial Supporter:

This activity is supported by educational funding provided by Amgen.

This AudioEducate activity, available through the Alexa app, is comprised of an expert commentary interview that highlights the most pertinent & relevant content from the "Dyslipidemia/Atherosclerosis" session at 2018 CMHC West meeting.

Christie Ballantyne, MD and Marc Sabatine, MD—two leading experts in the field of cardiometabolic health—discuss the PCSK9 inhibitor cardiovascular outcomes trials, FOURIER, and ODYSSEY outcomes, and the relevance to treatment of ASCVD in the everyday clinical setting. The interview additionally explores the efficacy and safety of PCSK9 inhibitors: specifically, the safety of very low LDL-C. Dr. Ballantyne and Dr. Sabatine examine the future of LDL-C reduction in patients with high risk of ASCVD through a discussion surrounding emerging agents. This audio educational activity is designed to equip healthcare providers with the necessary knowledge to address the clinical challenges in non-statin drugs, and navigate newly emerging approaches.